Cervical cancer vaccine, Cervarix, slowed by FDA
Filed under: Drug, Prevention, Cervical Cancer
The Food an Drug Administration is not going to grant a priority review to its experimental cancer vaccine Cervarix. Adding pressure GlaxoSmithKline’s controversy surrounding its diabetes drug Avandia.
Cervarix will now have to go through a standard 10 month review, instead of going the fast track route. The company is defending its diabetes drug after a study published in the New England Journal of Medicine said that those taking the drug are at greater risks of heart attacks.
GlaxoSmithKline expects to market the drug Cervarix in the United States sometime in 2008.
Read | Permalink | Email this | Linking Blogs | Comments
Original post by Kristina Collins
No comments yet. Be the first.
Leave a reply
Cervical cancer vaccine, Cervarix, slowed by FDA
Filed under: Drug, Prevention, Cervical Cancer
The Food an Drug Administration is not going to grant a priority review to its experimental cancer vaccine Cervarix. Adding pressure GlaxoSmithKline’s controversy surrounding its diabetes drug Avandia.
Cervarix will now have to go through a standard 10 month review, instead of going the fast track route. The company is defending its diabetes drug after a study published in the New England Journal of Medicine said that those taking the drug are at greater risks of heart attacks.
GlaxoSmithKline expects to market the drug Cervarix in the United States sometime in 2008.
Read | Permalink | Email this | Linking Blogs | Comments
Original post by Kristina Collins
No comments yet. Be the first.
Leave a reply